Géraldine Cizeron-Clairac
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Géraldine Cizeron-Clairac has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ivan Bièche
Department of Genetics, Institut Curie, Paris, France
2 shared publications - Keltouma Driouch
Institut Curie, Hôpital René Huguenin, Laboratoire d’oncogénétique
2 shared publications - Rosette Lidereau
Oncogenetic Laboratory, Institut Curie, Hospital René Huguenin, Saint-Cloud, France
2 shared publications - Sophie Vacher
Department of Genetics, Institut Curie, Paris Cité University, Paris, France
2 shared publications - Aurélie Susini
Laboratoire d'Oncogénétique, Institut Curie, Hôpital René Huguenin, 35 Rue Dailly, Saint-Cloud, F-92210, France
1 shared publication - Catherine Andrieu
Laboratoire d'Oncogénétique, Institut Curie, Hôpital René Huguenin, 35 Rue Dailly, Saint-Cloud, F-92210, France
1 shared publication
Latest Publications
- Open Access
- 13 February 2012
- Published by Springer Nature in Breast Cancer Research
- Vol. 14 (1) , R28
PIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
Introduction: PIK3CA is the oncogene showing the highest frequency of gain-of-function mutations in breast cancer, but the prognostic value of PIK3CA mutation status is controversial. Methods: We investigated the prognostic significance of PIK3CA mutation status in a series of 452 patients with unilateral invasive primary breast cancer and known long-term outcome (median follow-up 10 years). Results: PIK3CA mutations were identified in 151 tumors (33.4%). The frequency of PIK3CA mutations differed markedly according to hormone receptor (estrogen receptor alpha [ERα] and progesterone receptor [PR]) and ERBB2 status, ranging from 12.5% in the triple-negative subgroup (ER-/PR-/ERBB2-) to 41.1% in the HR+/ERBB2- subgroup. PIK3CA mutation was associated with significantly longer metastasis-free survival in the overall population (P = 0.0056), and especially in the PR-positive and ERBB2-positive subgroups. In Cox multivariate regression analysis, the prognostic significance of PIK3CA mutation status persisted only in the ERBB2-positive subgroup. Conclusions: This study confirms the high prevalence of PIK3CA mutations in breast cancer. PIK3CA mutation is an emerging tumor marker which might become used in treatment-choosing process. The independent prognostic value of PIK3CA mutation status in ERBB2-positive breast cancer patients should be now confirmed in larger series of patients included in randomized prospective ERBB2-based clinical trials.
- 13 February 2012
- Published by Springer Nature in Breast Cancer Research
- Vol. 14 (1) , R28
Open AccessPIK3CAmutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
Introduction: PIK3CA is the oncogene showing the highest frequency of gain-of-function mutations in breast cancer, but the prognostic value of PIK3CA mutation status is controversial. Methods: We investigated the prognostic significance of PIK3CA mutation status in a series of 452 patients with unilateral invasive primary breast cancer and known long-term outcome (median follow-up 10 years). Results: PIK3CA mutations were identified in 151 tumors (33.4%). The frequency of PIK3CA mutations differed markedly according to hormone receptor (estrogen receptor alpha [ERα] and progesterone receptor [PR]) and ERBB2 status, ranging from 12.5% in the triple-negative subgroup (ER-/PR-/ERBB2-) to 41.1% in the HR+/ERBB2- subgroup. PIK3CA mutation was associated with significantly longer metastasis-free survival in the overall population (P = 0.0056), and especially in the PR-positive and ERBB2-positive subgroups. In Cox multivariate regression analysis, the prognostic significance of PIK3CA mutation status persisted only in the ERBB2-positive subgroup. Conclusions: This study confirms the high prevalence of PIK3CA mutations in breast cancer. PIK3CA mutation is an emerging tumor marker which might become used in treatment-choosing process. The independent prognostic value of PIK3CA mutation status in ERBB2-positive breast cancer patients should be now confirmed in larger series of patients included in randomized prospective ERBB2-based clinical trials.
- Open Access
- 1 January 2011
- Published by Springer Nature in Molecular Cancer
- Vol. 10 (1) , 23
Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy
Aneuploidy and chromosomal instability (CIN) are common abnormalities in human cancer. Alterations of the mitotic spindle checkpoint are likely to contribute to these phenotypes, but little is known about somatic alterations of mitotic spindle checkpoint genes in breast cancer.
- 1 January 2011
- Published by Springer Nature in Molecular Cancer
- Vol. 10 (1) , 23
Open AccessExpression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy
Aneuploidy and chromosomal instability (CIN) are common abnormalities in human cancer. Alterations of the mitotic spindle checkpoint are likely to contribute to these phenotypes, but little is known about somatic alterations of mitotic spindle checkpoint genes in breast cancer.